Regeneron Pharmaceuticals, Inc.

-2.70 (-0.49%)
Earnings Announcements

Sanofi: EPO Rules In Sanofi And Regeneron's Favour On Praluent

Published: 10/29/2020 14:05 GMT
Regeneron Pharmaceuticals Inc (REGN) - European Patent Office Rules in Favor of Sanofi and Regeneron Concerning Praluent® (alirocumab).
Ruling Invalidates Amgen's European Patent Claims Directed to Pcsk9 Antibodies Relevant to Praluent(®) (alirocumab).
Praluent(®) (alirocumab) Continues to Be Available in European Countries Where It is Approved for Use and for Sale.
Revenue is expected to be $2.41 Billion
Adjusted EPS is expected to be $8.32

Next Quarter Revenue Guidance is expected to be $2.43 Billion
Next Quarter EPS Guidance is expected to be $8.77

More details on our Analysts Page.